Systemic agents, such as multi-kinase inhibitors, have achieved great progress since 2007, and combined anti-vascular endothelial growth factor (VEGF) or tyrosine kinase inhibitors (TKIs) with immune checkpoint blockades (ICBs) has been endorsed as the new standard of care in first-line treatment for advanced HCC [2]. Here, VEGFA is linked to hepatocellular carcinoma.